These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 6268052)

  • 1. Difference between influences of homologous and heterologous maternal antibodies on response to serotype-2 and serotype-3 Marek's disease vaccines.
    King D; Page D; Schat KA; Calnek BW
    Avian Dis; 1981; 25(1):74-81. PubMed ID: 6268052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of cell-free or cell-associated turkey herpesvirus vaccine against Marek's disease in chickens as influenced by maternal antibody, vaccine dose, and time of exposure to Marek's disease virus.
    Eidson CS; Page RK; Kleven SH
    Avian Dis; 1978; 22(4):583-97. PubMed ID: 219826
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of maternal antibody on efficacy of embryo vaccination with cell-associated and cell-free Marek's disease vaccine.
    Sharma JM; Graham CK
    Avian Dis; 1982; 26(4):860-70. PubMed ID: 6297450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of vaccinal immunity against Marek's disease.
    Witter RL; Offenbecker L
    Avian Dis; 1978; 22(3):396-408. PubMed ID: 211999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of B-haplotype on the relative efficacy of Marek's disease vaccines of different serotypes.
    Bacon LD; Witter RL
    Avian Dis; 1993; 37(1):53-9. PubMed ID: 8383961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serotype specificity of B-haplotype influence on the relative efficacy of Marek's disease vaccines.
    Bacon LD; Witter RL
    Avian Dis; 1994; 38(1):65-71. PubMed ID: 8002902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: comparative efficacy.
    Witter RL
    Avian Dis; 1987; 31(4):752-65. PubMed ID: 2831867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of CVI988/Rispens and R2/23, two prototype vaccine strains of serotype 1 Marek's disease virus.
    Witter RL; Lee LF; Fadly AM
    Avian Dis; 1995; 39(2):269-84. PubMed ID: 7677647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective efficacy of Marek's disease virus (MDV) CVI-988 CEF65 clone C against challenge infection with three very virulent MDV strains.
    de Boer GF; Groenendal JE; Boerrigter HM; Kok GL; Pol JM
    Avian Dis; 1986; 30(2):276-83. PubMed ID: 3015113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humoral immune responses to inactivated oil-emulsified Marek's disease vaccine.
    Lee LF; Witter RL
    Avian Dis; 1991; 35(3):452-9. PubMed ID: 1659363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Embryo vaccination against Marek's disease with serotypes 1, 2 and 3 vaccines administered singly or in combination.
    Sharma JM; Witter RL
    Avian Dis; 1983; 27(2):453-63. PubMed ID: 6307248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus.
    Karpathy RC; Firth GA; Tannock GA
    Aust Vet J; 2002; 80(1-2):61-6. PubMed ID: 12180882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protection and synergism by recombinant fowl pox vaccines expressing genes from Marek's disease virus.
    Nazerian K; Witter RL; Lee LF; Yanagida N
    Avian Dis; 1996; 40(2):368-76. PubMed ID: 8790888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Experiments with the simultaneous or combined vaccination of chicks against Marek's disease and Newcastle disease].
    Cholakova R; Stanilov Kh; Aleksiev N
    Vet Med Nauki; 1978; 15(7):19-26. PubMed ID: 219586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New serotype 2 and attenuated serotype 1 Marek's disease vaccine viruses: selected biological and molecular characteristics.
    Witter RL; Silva RF; Lee LF
    Avian Dis; 1987; 31(4):829-40. PubMed ID: 2831870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of Marek's disease vaccine.
    Ben-Nathan D; Lustig S
    Adv Biotechnol Processes; 1990; 14():347-65. PubMed ID: 2171556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of infectious bursal disease virus on protection against Marek's disease by turkey herpesvirus vaccine.
    Sharma JM
    Avian Dis; 1984; 28(3):629-40. PubMed ID: 6091603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective immunity to infectious bronchitis in broilers vaccinated against Marek's disease either in ovo or at hatch and against infectious bronchitis at hatch.
    Avakian AP; Wakenell PS; Grosse D; Whitfill CE; Link D
    Avian Dis; 2000; 44(3):536-44. PubMed ID: 11007000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of cell associated vaccines against Marek's disease virus grown in a continuous cell line from chickens.
    Geerligs H; Quanz S; Suurland B; Spijkers IE; Rodenberg J; Davelaar FG; Jongsma B; Kumar M
    Vaccine; 2008 Oct; 26(44):5595-600. PubMed ID: 18706949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection of chickens against very virulent infectious bursal disease virus (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2.
    Tsukamoto K; Kojima C; Komori Y; Tanimura N; Mase M; Yamaguchi S
    Virology; 1999 May; 257(2):352-62. PubMed ID: 10329546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.